Does angiotensin II modulate erythropoietin production in HepG2 cells?

Nephron - Experimental Nephrology

Volumn 98, Issue 4, 2004, Pages

  Benöhr, Peter ^a   Harsch, Simone ^a   Proksch, Barbara ^a   Gleiter, Christoph H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Angiotensin II; Erythropoietin; HepG2 cells; Hypoxia; Interleukin 22; LightCycler RT PCR

Indexed keywords

ANGIOTENSIN; CYCLOPHILIN; ERYTHROPOIETIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; MESSENGER RNA;

ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE EXPRESSION; HEMODYNAMICS; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY BLOOD FLOW; MEASUREMENT; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL HYPOXIA; DRUG EFFECT; GENETICS; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HORMONAL REGULATION;

ANGIOTENSIN II; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; ERYTHROPOIETIN; GENE EXPRESSION; HUMANS; INTERLEUKINS; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 11244299402     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081556     Document Type: Article

References (36)

1. Maxwell PH, Ferguson DJP, Nicholls LG, et al: Sites of erythropoietin production. Kidney Int 1997;51:393-401.
2. Freudenthaler SM, Schreeb KH, Körner T, Gleiter CH: Angiotensin II increases erythropoietin production in healthy volunteers. Eur J Clin Invest 1999;29:816-823.
3. Freudenthaler SM, Lucht I, Schenk T, Gleiter CH: Dose-dependent effect of angiotensin II on human erythropoietin production. Pfl ügers Archiv/Eur J Physiol 2000;439:838-844.
4. Gossmann J, Burkhardt R, Harder S, et al: Angiotensin II infusion increases plasma erythropoietin levels via angiotensin II type 1 receptor-dependent pathway. Kidney Int 2001;60:83-86.
5. Gleiter CH: Posttransplant erythrocytosis: A model for the investigation of the pharmacological control of renal erythropoietin production? Int J Clin Pharmacol Ther 1996; 34: 489-492.
6. Montanaro D, Groupuzzo M, Boscutti G, Risaliti A, Bresadola F, Mioni G: Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: Efficacy, safety and action mechanism. Clin Nephrol 2000;53:47-51.
7. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000;35:154-156.
8. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T: Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984;4:355-360.
9. Hayashi K, Hasegawa K, Kobayashi S: Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int 2001;60:1910-1916.
10. Badzynska B, Grzelec-Mojzesowicz M, Dobrowolski L, Sadowski J: Differential effect of angiotensin II on blood circulation in the renal medulla and cortex of anaesthetised rats. J Physiol 2002;538:159-166.
11. Goldberg MA, Glass GA, Cunningham JM, Bunn HF: The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987;84:7972-7976.
12. Li J, Brasier AR: Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-κB p65) transcription factor one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol 1996;10:252-264.
13. Zhong H, Simons JW: Direct comparison of GAPDH, β-actin, cyclophilin and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999;259:523-526.
14. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC: Interleukin (IL)-22 activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002;277:33676-33682.
15. Ferri C, Desideri G, Baldoncini R, et al: Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels. Clin Sci 1999;96:261-270.
16. Higueruelo S, Romero R: Angiotensin II requires PDGF-BB to induce DNA synthesis in rat mesangial cells cultured in an exogenous insulin-free medium. Nephrol Dial Transplant 1997;12:694-700.
17. Jacobs K, Shoemaker C, Rudersdorf R, et al: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-810.
18. Nagao M, Suga H, Okano M, et al: Nucleotide sequence of rat erythropoietin. Biochim Biophys Acta 1992;1171:99-102.
19. Coezy ED, Corvol P, Howlett AC: Involvement of a pertussis toxin-sensitive G protein in the regulation of angiotensinogen production by an angiotensin II analog in HepG2 cells. Cell Signal 1990;2:67-76.
20. Mesples B, Plaisant F, Gressens P: Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice. Brain Res Dev Brain Res 2003;141:25-32.
21. Darby IA, Coezy ED, Mizrahi J, et al: Regulation of angiotensinogen production by angiotensin II analogues. J Hypertens 1988; 6(suppl):446-448.
22. Sodhi CP, Kanwar YS, Sahai A: Hypoxia and high glucose upregulate AT 1 receptor expression and potentiate angiotensin II-induced proliferation in VSM cells. Am J Physiol 2003;284:H846-H852.
23. Ip SP, Chan YW, Leung PS: Effects of chronic hypoxia on the circulating and pancreatic renin-angiotensin system. Pancreas 2002;25:296-300.
24. Miyoshi M, Nagata K, Imoto T, Goto O, Ishida A, Watanabe T: Angiotensin II is involved in the LPS-induced production of proinfl ammatory cytokines in dehydrated rats. Am J Physiol 2003;284:R1092-R1097.
25. Jamaluddin M, Meng T, Sun J, Boldogh I, Han Y, Brasier AR: Angiotensin II induces nuclear factor (NF)-κB1 isoforms to bind the angiotensinogen gene acute-phase response element: A stimulus-specific pathway for NF-κB activation. Mol Endocrinol 2000;14:99-113.
26. Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR: Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J Interferon Cytokine Res 2002;22:1099-1112.
27. Xu W, Presnell SR, Parrish-Novak J, et al: A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci USA 2001;98:9511-9516.
28. Nagem RA, Colau D, Dumoutier L, Renauld JC, Ogata C, Polikarpo I: Crystal structure of recombinant human interleukin-22. Structure 2002;10:1051-1062.
29. Guzdek A, Stalinska K, Guzik K, Koj A: Differential responses of hematopoietic and nonhematopoietic cells to anti-inflammatory cytokines: IL-4, IL-13 and IL-10. J Physiol Pharmacol 2000; 51: 387-399.
30. Costa-Giomi P, Caro J, Weinmann R, et al: Enhancement by hypoxia of human erythropoietin gene transcription in vitro. J Biol Chem 1990;265:10185-10188.
31. Fandrey J, Bunn HF: In vivo and in vitro regulation of erythropoietin mRNA: Measurement by competitive polymerase chain reaction. Blood 1993;81:617-623.
32. Ratcliffe PJ, Jones RW, Phillips RE, Nicholls LG, Bell JI: Oxygen-dependent modulations of erythropoietin mRNA levels in isolated rat kidneys studied by RNase protection. J Exp Med 1990;172:657-660.
33. Cervenka L, Wang CT, Navar LG: Effects of acute AT 1 receptor blockade by candesartan on arterial pressure and renal function in rat. Am J Physiol 1998;274:F940-F945.
34. Manotham K, Tanaka T, Matsumoto M, et al: Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004;15:1277-1288.
35. 2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003;94:39-46.
36. Freudenthaler S, Benöhr P, Grenz A, Selzer T, Schmidt T, Mörike K, Osswald H, Gleiter CH: Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans? Br J Clin Pharmacol 2003;56:378-387.